COVID-19 in Liver Transplant Patients: A University Hospital Experience

• Published in: Transplantation proceedings Vol. 55; no. 5; pp. 1223 - 1225
• Main Authors: Eren-Kutsoylu, Oya Ozlem, Egeli, Tufan, Agalar, Cihan, Ozbilgin, Mucahit, Ozgen-Alpaydin, Aylin, Unek, Tarkan, Avkan-Oguz, Vildan
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2023
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2023.01.032

•Follow-up of late post-liver transplant patients is the same as in a healthy population.•Changes in immunosuppressive agents are not recommended in liver transplant patients.•COVID-19 immunization is strongly recommended in liver transplant patients. We aimed to examine the comorbidity, disease progress, and vaccination status of liver transplant patients followed up in our hospital who had COVID-19. Liver transplant patients with COVID-19 were included between 11 March 2020 and 15 September 2022. Demographic data, disease progress, and COVID-19 vaccines were recorded. The SPSS 24.0 (IBM SPSS, Inc, Armonk, NY, United States) program was used for analysis. The data were analyzed using the χ2 test. P values < .05 were considered clinically significant. Sixteen SARS-CoV-2 polymerase chain reaction (+) patients were detected. Twelve (75.0%) patients were male; the mean age was 49.56 ± 14.0 years (24-76 years). The mean transplant time was 156.69 ± 54.05 months. Four (25.0%) of the 5 (31.3%) patients with comorbidities had hypertension, and 1 (6.3%) had diabetes. None of the patients had an underlying lung disease. All the patients received immunosuppressive therapy, and the most common combination was antimetabolite and calcineurin inhibitor (9 patients [69.2%]). Nine patients (56.3%) had a fever, whereas 6 (37.5%) had respiratory symptoms. Two (33.3%) had pneumonia. Five (31.4%) patients were hospitalized, and 1 (20%) was admitted to the intensive care unit due to non-invasive mechanical ventilation needs. No patient died due to COVID-19. A statistically significant correlation was found between the presence of fever, respiratory symptoms, and hospitalization (P < .05). Of those vaccinated, 10 (66.7%) were infected before the COVID-19 vaccination. The course of COVID-19 in liver recipients without any underlying disease other than transplantation is not different from that in the healthy population. Immunosuppressive therapy was continued in patients with the disease, and two-thirds did not require hospitalization.